In the Netherlands, KeyGene’s United States patent (US 8,815,512) protecting Sequence-Based Genotyping (SBG) technology was upheld by the United States Patent and Trademark Office, following ex parte reexamination initiated by Cornell University. KeyGene’s methods are widely used to score thousands of DNA markers in plants, animals and model, thereby contributing to meeting the challenges of sustainable agriculture and food supply. The patent is part of KeyGene’s global dominant patent portfolio protecting methods for simultaneous polymorphism discovery and genotyping, including SBG, GBS, RAD, ddRAD and related methods.
Michiel van Eijk, Ph.D., CSO of KeyGene, said in their press release, “We are very satisfied with this confirmation of the validity of the ‘512 patent by the USPTO. This reexamination affirmed all seventeen disputed claims, which further strengthens our SBG patent portfolio and endorses that KeyGene is the inventor of Sequence-Based Genotyping.”